Anatara Lifesciences is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Our lead product Detach™ is a natural product that will help address global concerns around the overuse of antibiotics in animals and their feed that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Latest news All news
Wilson HTM today released a research and valuation report on Anatara Lifesciences (ANR). The report initiated a Speculative BUY rating and a price target of 60 cps.
“Bull case valuations can push north of $2.50 per share if project success and international marketing partners are delivered over the next few years.”
Please open the attached PDF to view the report.
Anatara Lifesciences is pleased to announce it has begun the first pivotal field trial of its lead product Detach™, a non-antibiotic, natural product to prevent and treat diarrhoea in piglets.
Please click here to view the announcement.